Cassava Sciences Inc - Company Profile
Powered by 
All the data and insights you need on Cassava Sciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cassava Sciences Inc Strategy Report
- Understand Cassava Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cassava Sciences Inc (Cassava Sciences), formerly Pain Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops drugs for the treatment of neuroinflammation and neurodegenerative diseases, with a special focus on Alzheimer’s disease. The company’s lead product candidate Simufilam is a small molecule being developed in phase 3 clinical trials for treatment of Alzheimer’s disease. The clinical trials are conducted in phase3 studies such as Rethink-ALZ and Refocus-ALZ. It is also investigating SavaDx, a blood-based diagnostic for detection of Alzheimer's disease. Major investors include national institute of health of health (NIH), National Institute on aging (NIA). Cassava Sciences is headquartered in Austin, Texas, the US.
Headquarters
United States of America
Address
6801 N Capital Of Texas Highway, Building 1; Suite 300, Austin, 78731
Website
www.cassavasciences.com
Telephone
1 512 5012444
No of Employees
29
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAVA (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-27.5%
(2022 vs 2021)
Market Cap*
$919.8M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Cassava Sciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Product Pipeline:- |
| Simufilam- Alzheimer’s Disease |
| SavaDx - Blood-based Diagnostic to Detect Alzheimer’s Disease |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In March, the company completed an interim safety review of simufilam in ongoing Phase 3 clinical trials in patients with Alzheimer’s disease. |
| 2023 | Others | In May, the company finished dosing patients in its cognition maintenance study (CMS) of simufilam for the treatment of Alzheimer’s disease and dementia. |
| 2022 | Contracts/Agreements | In November, the company entered into an agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock. |
Competitor Comparison
| Key Parameters | Cassava Sciences Inc | Eli Lilly and Co | Amgen Inc | Biogen Inc | Eisai Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Japan |
| City | Austin | Indianapolis | Thousand Oaks | Cambridge | Bunkyo-Ku |
| State/Province | Texas | Indiana | California | Massachusetts | Tokyo |
| No. of Employees | 29 | 43,000 | 26,700 | 7,570 | 11,076 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Remi Barbier | President; Chairman; Chief Executive Officer | Executive Board | 1998 | 63 |
| Eric J. Schoen | Chief Financial Officer | Senior Management | 2018 | 54 |
| James W. Kupiec, MD | Chief Medical Officer | Senior Management | 2022 | 70 |
| R. Christopher Cook | General Counsel; Senior Vice President | Senior Management | 2022 | - |
| Lindsay H. Burns, Ph.D. | Senior Vice President - Neuroscience | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward